Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2003

View Archived Issues

Four related series of gamma-secretase inhibitors designed by Merck researchers

Kirin Brewery patent covers M-CSF inhibitors able to prevent bone metastasis and osteoporosis

New tyrosine kinase inhibitors, their preparation and use covered by Merck patent

Chugai researchers discover novel biguanide-based antidiabetic agents

Novel HDAC inhibitors idenified at AstraZeneca

Ximelagatran superior to warfarin in preventing VTE after total knee replacement

Clinical benefits of gene therapy with Ad-CD154 for CLL

Preliminary evaluation of NS-1209 in patients with status epilepticus

Potential use of bispecific antibody Bi20 in patients with B-cell lymphoma

Pixantrone shows antitumor efficacy in relapsed/refractory NHL

Active Biotech TTS development to focus on TTS CD3

AEterna focuses Neovastat program on NSCLC

APD-356 completes preclinical testing

Eligard approved in Australia

Clinical effect observed in phase I study of BCX-1777 in T-cell malignancies

Second phase I study of ETC-642 shows evidence of cholesterol mobilization

Enrollment completed in European rhATIII study

Interim analysis reported for Infergen/Actimmune in hepatitis C nonresponders

Enrollment under way in pivotal INSPIRE study of Actimmune for IPF

Riquent NDA submitted to FDA

New clinical study evaluates SEPA-enhanced testosterone

Phase II trials evaluate Vitaxin for prostate cancer and psoriasis

MBI-2401 is lead development candidate from Micrologix lipopeptide program

Vertex and OHSU enter drug discovery and development collaboration

Preclinical findings for SGN-40 summarized at ASH meeting

Oxycyte studied for cardiac surgery

Fuzeon 48-week data submitted to support full FDA approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Harbour Biomed closes busy year with $1B+ BMS deal
BioWorld
Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies....
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...